Block Grant U50CI024407

This Cooperative Agreement award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will leverage systems biology approaches to identify novel correlates of protection and biomarkers for optimal immune responses against influenza. The project, titled "Influenza Modeling of Correlates of Protection for Optimal Immune Dynamics and Evolution," will integrate longitudinal multi-omic datasets...

This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop computational models that can accurately predict the breadth and durability of influenza vaccine responses. The $1,246,617.00 award, with a performance period from December 2024 to November 2029, will: Capture existing influenza vaccine data and generate new experimental data connecting immune...

This $2,074,701 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is funding a multi-year research program at Emory University to advance understanding of the biological and physical drivers of influenza A virus transmission in humans. The key objectives of the research program are to: 1) Define the dynamics of viral load, immune responses, and infectious aerosol production in humans...

This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), will leverage machine learning to develop novel immunogen candidates for broadly protective influenza vaccines. The $1,195,056 award, effective from May 2025 to April 2030, aims to integrate artificial intelligence/machine learning (AI/ML) and traditional computational biology to create a new class of immunogens...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $183,541 over 5 years to support an investigation of within-household transmission of influenza in low-resource settings. The research, led by a principal investigator at Yale University, aims to quantify influenza spread within households and develop a model to evaluate the effectiveness of interventions like...

This $600,000 project grant awarded by the National Science Foundation (NSF) Social, Behavioral, and Economic Sciences (CFDA 47.075) program aims to enhance influenza forecasting through an integrated platform for user-generated temporal forecasts. The project takes a participatory modeling approach to guide the construction of a human judgment platform that generates temporal forecasts of infectious disease trajectories. The key goals are to: 1) identify the factors and decision-making...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,225,986 Cooperative Agreement (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Chicago to conduct research on computational models of the adaptive immune response to influenza. The study aims to describe the conditions under which strong, durable, and broadly protective adaptive immune responses to influenza arise, and to use statistical and mechanistic models to understand how these...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Orlance, Inc., a woman-owned small business, a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop an enhanced seasonal influenza DNA vaccine. The project aims to combine the advantages of a closely matched seasonal influenza vaccine with a universal influenza vaccine to provide more robust and durable protection, especially for the elderly and immunocompromised...

This Project Grant award, valued at $792,687.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the structural features of sialoglycans necessary for influenza A virus (IAV) infection and adaptation across various host species. The key activities under this award include: 1) using CRISPR/Cas9 techniques to truncate different types of sialoglycans in human lung...

This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), focuses on studying the factors that influence the efficiency of influenza A virus (IAV) infection in a recipient host. The $146,922 award will support research to investigate how the mode of viral exposure (direct contact, self-inoculation, or airborne transmission) and environmental conditions, such as temperature and...